No Data
No Data
【Hong Kong Stock Connect】Kaiser Pharmaceuticals (02171) will release clinical data for Saikai Ze, CT071, and CT0590 at the 66th American Society of Hematology Annual Meeting.
King's Financial News | Koji Pharmaceutical (02171) announced that it will present clinical data on Sikaize (Zerovokinorunsa injection, product number: CT053, a self-targeting BCMA CAR-T product), CT071 (a self-targeting GPRC5D CAR-T candidate product), and CT0590 (a self-targeting BCMA allogeneic CAR-T candidate product) at the 66th American Society of Hematology ("ASH") Annual Meeting. Abstracts and further information will be released after November 5, 2024, Eastern Time. Sikaize is a treatment used for
China Medical System -B (02171): Data from Saikai Ze, CT071 and CT0590 will be presented at the 2024 ASH Annual Meeting.
Kangji Pharmaceutical - B (02171) announced that they will showcase Saikai Ze at the 66th American Society of Hematology Annual Meeting.
HK Stocks Surge | Saisheng Pharmaceutical-B (02171) surges over 13% again, the company has submitted an application to lift the clinical hold, and the commercialization of Saixize is progressing smoothly.
China Resources Pharmaceutical Group Limited-B (02171) rose by over 13%, as of the time of publication, it increased by 12.67%, trading at 5.07 Hong Kong dollars, with a turnover of 28.1184 million Hong Kong dollars.
Express News | CARsgen Therapeutics Holdings Ltd - Application to Request Lifting Clinical-Holds Submitted to FDA
The commercialization of the product is difficult to support alone, and has the identity of the largest bearish event within the year for Science and Economy Pharmaceutical (02171) through the Hong Kong Stock Connect program?
For SciClone Pharmaceuticals-B (02171), the most important milestone event in 2024 is the successful commercialization of the core variety CT053 in March this year. However, the commercialization of the first product did not bring further valuation leap on the secondary market to the company, instead it led to a continuously declining stock price.
CARSGEN-B: INTERIM REPORT 2024
No Data
No Data